DONOR- AND DOSE- SPECIFIC ENDOTHELIAL ACTIVATION AND CLINICAL OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (EBMT 2026) - Mar 14, 2026 - Abstract #B044; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "At our institution, PTCy-based prophylaxis has been progressively implemented since 2013; tacrolimus (TK) is routinely combined, and mycophenolate mofetil (MMF) is added in haploidentical transplants (haplo-HCT)...All CMV-positive recipients received letermovir, and all patients received G-CSF from day +7.As reported in Table 1, baseline characteristics were balanced... Endothelial activation after allo-HCT with PTCy appears influenced by donor type and PTCy dosing. Haplo-HCT showed the highest endothelial stress and the greatest burden of early infectious and cardiovascular complications, despite similar GVHD rates and survival outcomes across groups. Results support the conduction of studies evaluating whether early biomarker dynamics can predict post-transplant complicationss."
Clinical • Clinical data • Post-transplantation • Acute Graft versus Host Disease • Cardiovascular • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Transplantation • TNFRSF1A
|
|
Queralt Salas1; Blanca De Moner1; María Suárez-LLedó1; Julia Martinez-Sachez1; Ana Belén Moreno-Castaño1; Laua Guardia1; Cristina Moreno1; Esther Carcelero1; Paola Charry1; Joan Cid1; Miquel Lozano1; Begoña Fernández1; Laura Rosiñol1; Enric Carreras2; Francesc Fernández-Avilés1; Montserrat Rovira1; Carmen Martínez1; Maribel Díaz-Ricart1
|